BACKGROUND: There is substantial variation in how histologic definitions and scoring systems of non-alcoholic fatty liver disease (NAFLD) are operationalised. AIM: To develop a consensus-based framework for standardising histologic assessment of liver biopsies in clinical trials of NAFLD. METHODS: An expert panel of 14 liver pathologists and three hepatologists was assembled. Using modified RAND/University of California Los Angeles appropriateness methodology, 130 items derived from literature review and expert opinion were rated by each panel member on a 1-9 scale. Disagreement was defined as ≥5 ratings in the lowest (1-3) and highest (7-9) categories. Items were classified as inappropriate (median 1-3.5 without disagreement), uncertain (median 3.5-6.5 or any median with disagreement) or appropriate (median 6.5-9 without disagreement). Survey results were discussed as a group before voting. RESULTS: Current measures of disease activity and fibrosis may not fully capture important features of non-alcoholic steatohepatitis (NASH). Alternative methods to evaluate ballooning degeneration are needed. Panellists were uncertain whether portal inflammation, degree of steatosis and Mallory-Denk bodies are important measures of disease activity. Furthermore, it was felt that current staging systems do not capture the full spectrum of fibrosis in NASH. A consensus definition and sub-stages for bridging fibrosis are needed. The severity of perisinusoidal fibrosis should be captured at all stages. Lastly, a method to evaluate features of fibrosis regression should be developed. CONCLUSION: The operating properties of the modifications proposed should be evaluated prospectively to determine reliability and responsiveness.
BACKGROUND: There is substantial variation in how histologic definitions and scoring systems of non-alcoholic fatty liver disease (NAFLD) are operationalised. AIM: To develop a consensus-based framework for standardising histologic assessment of liver biopsies in clinical trials of NAFLD. METHODS: An expert panel of 14 liver pathologists and three hepatologists was assembled. Using modified RAND/University of California Los Angeles appropriateness methodology, 130 items derived from literature review and expert opinion were rated by each panel member on a 1-9 scale. Disagreement was defined as ≥5 ratings in the lowest (1-3) and highest (7-9) categories. Items were classified as inappropriate (median 1-3.5 without disagreement), uncertain (median 3.5-6.5 or any median with disagreement) or appropriate (median 6.5-9 without disagreement). Survey results were discussed as a group before voting. RESULTS: Current measures of disease activity and fibrosis may not fully capture important features of non-alcoholic steatohepatitis (NASH). Alternative methods to evaluate ballooning degeneration are needed. Panellists were uncertain whether portal inflammation, degree of steatosis and Mallory-Denk bodies are important measures of disease activity. Furthermore, it was felt that current staging systems do not capture the full spectrum of fibrosis in NASH. A consensus definition and sub-stages for bridging fibrosis are needed. The severity of perisinusoidal fibrosis should be captured at all stages. Lastly, a method to evaluate features of fibrosis regression should be developed. CONCLUSION: The operating properties of the modifications proposed should be evaluated prospectively to determine reliability and responsiveness.
Authors: Ravi Juluri; Raj Vuppalanchi; John Olson; Aynur Unalp; Mark L Van Natta; Oscar W Cummings; James Tonascia; Naga Chalasani Journal: J Clin Gastroenterol Date: 2011-01 Impact factor: 3.062
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Michelle M Richardson; Julie R Jonsson; Elizabeth E Powell; Elizabeth M Brunt; Brent A Neuschwander-Tetri; Prithi S Bhathal; John B Dixon; Martin D Weltman; Herbert Tilg; Alexander R Moschen; David M Purdie; Anthony J Demetris; Andrew D Clouston Journal: Gastroenterology Date: 2007-05-16 Impact factor: 22.682
Authors: Mohammad Shadab Siddiqui; Stephen A Harrison; Manal F Abdelmalek; Quentin M Anstee; Pierre Bedossa; Laurent Castera; Lara Dimick-Santos; Scott L Friedman; Katherine Greene; David E Kleiner; Sophie Megnien; Brent A Neuschwander-Tetri; Vlad Ratziu; Elmer Schabel; Veronica Miller; Arun J Sanyal Journal: Hepatology Date: 2018-02-22 Impact factor: 17.425
Authors: Marija Branković; Igor Jovanović; Marija Dukić; Tijana Radonjić; Svetlana Oprić; Slobodan Klašnja; Marija Zdravković Journal: Int J Mol Sci Date: 2022-05-05 Impact factor: 6.208
Authors: Rish K Pai; Vipul Jairath; Malcolm Hogan; Guangyong Zou; Oyedele A Adeyi; Quentin M Anstee; Bashar A Aqel; Cynthia Behling; Elizabeth J Carey; Andrew D Clouston; Kathleen Corey; Brian G Feagan; David E Kleiner; Christopher Ma; Stefanie C McFarlane; Mazen Noureddin; Vlad Ratziu; Mark A Valasek; Zobair M Younossi; Stephen A Harrison; Rohit Loomba Journal: Hepatology Date: 2022-04-06 Impact factor: 17.298